Extracorporeal Photopheresis in Dermatological Diseases.

Abstract

Extracorporeal photopheresis (ECP) is an apheresis procedure that is conventionally used as a first-line treatment for cutaneous and leukemic subtypes of T-cell lymphoma, such as Sezary's syndrome and mycosis fungoides. Over the past three decades, its immunotherapeutic properties have been tested on a variety of autoimmune conditions, including many dermatologic diseases. There is ample evidence of ECP's ability to modify leukocytes and alter cytokine production for certain dermatologic diseases that have been refractory to first-line treatments, such as atopic dermatitis. However, the evidence on the efficacy of ECP for the treatment of these dermatologic diseases is unclear and/or lacks sufficient evidence. The purpose of this paper is to review the literature on the utilization and clinical efficacy of ECP in the treatment of several [autoimmune] dermatologic diseases and discuss its applications, guidelines, recommendations, and future implementation for dermatologic diseases.

• Authors: Hanna Terhaar, Mohammad Saleem, Nabiha Yusuf
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 25 Issue 5 (Mar 05 2024) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 38474257 (Publication Type: Journal Article, Review)

Topics

• Humans
• Photopheresis (methods)
• Skin Neoplasms (pathology)
• Mycosis Fungoides (pathology)
• Blood Component Removal (methods)
• Sezary Syndrome (therapy)